PMID- 36327542
OWN - NLM
STAT- MEDLINE
DCOM- 20221130
LR  - 20221216
IS  - 1878-3279 (Electronic)
IS  - 0171-2985 (Linking)
VI  - 227
IP  - 6
DP  - 2022 Nov
TI  - The role of dendritic cells in neuroblastoma: Implications for immunotherapy.
PG  - 152293
LID - S0171-2985(22)00119-X [pii]
LID - 10.1016/j.imbio.2022.152293 [doi]
AB  - Neuroblastoma is a solid tumor, which is originated from some neural tissues. The 
      immune system including the innate and adaptive immune system fights against this 
      tumor. Dendritic cells (DCs) play an important role in this way by recognizing 
      tumor antigens and activating specific types of T cells. These cells are derived 
      from monocytes that are induced by inflammatory factors secreted by different 
      cells in the tumor microenvironment (TME). There are different types of DCs, 
      including monocyte-derived DCs (moDC), plasmacytoid DCs (pDC), conventional DCs 
      type 1 and 2 (cDC1 and cDC2), and Langerhans cells. DCs connect the innate and 
      the adaptive part of the immune system and have an important role in anti-tumor 
      immunity. There are some vaccines that involve specific types of DCs, which can 
      be used to prevent neuroblastoma. Also, we can use the combination of 
      inflammatory factors and DCs as a substitute for chemotherapy.
CI  - Copyright (c) 2022 Elsevier GmbH. All rights reserved.
FAU - Zafari, Rasa
AU  - Zafari R
AD  - Cancer Immunology Project (CIP), Universal Scientific Education and Research 
      Network (USERN), Tehran, Iran; School of Medicine, Tehran University of Medical 
      Sciences, Tehran, Iran. Electronic address: rasazafari22@gmail.com.
FAU - Razi, Sepideh
AU  - Razi S
AD  - Cancer Immunology Project (CIP), Universal Scientific Education and Research 
      Network (USERN), Tehran, Iran; School of Medicine, Iran University of Medical 
      Sciences, Tehran, Iran; Research Center for Immunodeficiencies, Children's 
      Medical Center, Tehran University of Medical Sciences, Tehran, Iran. Electronic 
      address: Sepidrazi1994@gmail.com.
FAU - Rezaei, Nima
AU  - Rezaei N
AD  - Research Center for Immunodeficiencies, Children's Medical Center, Tehran 
      University of Medical Sciences, Tehran, Iran; Department of Immunology, School of 
      Medicine, Tehran University of Medical Sciences, Tehran, Iran; Cancer Immunology 
      Project (CIP), Universal Scientific Education and Research Network (USERN), 
      Stockholm, Sweden. Electronic address: rezaei_nima@tums.ac.ir.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20221026
PL  - Netherlands
TA  - Immunobiology
JT  - Immunobiology
JID - 8002742
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Immunologic Factors)
SB  - IM
MH  - Humans
MH  - Immunotherapy
MH  - Dendritic Cells
MH  - Monocytes
MH  - Antigens, Neoplasm
MH  - *Neoplasms
MH  - *Neuroblastoma/therapy
MH  - Immunologic Factors
MH  - Tumor Microenvironment
OTO - NOTNLM
OT  - Dendritic cells
OT  - Immunotherapy
OT  - Inflammation
OT  - Neuroblastoma
OT  - Tumor microenvironment
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2022/11/04 06:00
MHDA- 2022/12/01 06:00
CRDT- 2022/11/03 19:14
PHST- 2022/03/09 00:00 [received]
PHST- 2022/09/09 00:00 [revised]
PHST- 2022/10/19 00:00 [accepted]
PHST- 2022/11/04 06:00 [pubmed]
PHST- 2022/12/01 06:00 [medline]
PHST- 2022/11/03 19:14 [entrez]
AID - S0171-2985(22)00119-X [pii]
AID - 10.1016/j.imbio.2022.152293 [doi]
PST - ppublish
SO  - Immunobiology. 2022 Nov;227(6):152293. doi: 10.1016/j.imbio.2022.152293. Epub 
      2022 Oct 26.